The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

4.00

Estimated average

burden

hours per

response:

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None **Names**

Entity Type

X Corporation

0001469443

Name of Issuer

Arcadia Biosciences, Inc.

Incorporation/Organization

Jurisdiction of

Limited Liability Company

General Partnership **Business Trust**

Other (Specify)

Limited Partnership

ARIZONA

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Arcadia Biosciences, Inc.

Street Address 2 Street Address 1

202 Cousteau Place

Suite 200 **State/Province/Country** ZIP/PostalCode **Phone Number of Issuer** City

95618 (530) 750-7077 CA **Davis**

3. Related Persons

Last Name First Name Middle Name

Rey Eric

> **Street Address 1 Street Address 2**

202 Cousteau Place Suite 200

> ZIP/PostalCode City State/Province/Country

CA **Davis** 95618

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Brandwein Steve

> **Street Address 1 Street Address 2**

2390 E. Camelback Road Suite 440

> City State/Province/Country ZIP/PostalCode

AZ. 85016 Phoenix

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Thatcher Jonathan

Street Address 1 Street Address 2

2390 E. Camelback Road Suite 440

City State/Province/Country ZIP/PostalCode

Phoenix AZ 85016

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Wong Mark

Street Address 1 Street Address 2

1941 Pearl Street

City State/Province/Country ZIP/PostalCode

Boulder CO 80302

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Reis James

Street Address 1 Street Address 2

3333 Lee Parkway Suite 1200

City State/Province/Country ZIP/PostalCode

Dallas TX 75219

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Collier David

Street Address 1 Street Address 2

One Embarcadaro Center Suite 3250

City State/Province/Country ZIP/PostalCode

San Francisco CA 94111

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services

Commercial Banking
Insurance
Health Insurance
Hospitals & Physicians
Computers

Investing Pharmaceuticals Telecommunications

Pooled Investment Fund Other Health Care X Other Technology

Is the issuer registered as Manufacturing Travel an investment company under Real Estate A and A

the Investment Company

Act of 10402

Real Estate

Airlines & Airports

Commercial

Lodging & Convent

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Residential **Business Services** Other Energy

Coal Mining

Electric Utilities

Environmental Services

Energy Conservation

Oil & Gas Other Energy

5. Issuer Size

OR **Revenue Range Aggregate Net Asset Value Range**

Other Real Estate

No Revenues No Aggregate Net Asset Value

\$1 - \$1,000,000 \$1 - \$5,000,000

\$5,000,001 - \$25,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 -\$25,000,001 - \$50,000,000 \$25,000,000

\$25,000,001 -\$50,000,001 - \$100,000,000 \$100,000,000

Over \$100,000,000 Over \$100,000,000 X Decline to Disclose Decline to Disclose Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) **Rule 505** Rule 504 (b)(1)(i) X Rule 506

Rule 504 (b)(1)(ii) Securities Act Section 4(5)

Rule 504 (b)(1)(iii) Investment Company Act Section 3(c)

> Section 3(c)(1)Section 3(c)(9)

Section 3(c)(2)Section 3(c)(10)

Section 3(c)(3)Section 3(c)(11)

Section 3(c)(4)Section 3(c)(12)

Section 3(c)(5)Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2008-07-11 First Sale Yet to Occur

Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity Debt

Option, Warrant or Other Right to Acquire Another Security

Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities

Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$1 USD

12. Sales Compensation

Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$15,200,000 USD or Indefinite

Total Amount Sold \$15,200,000 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

9

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$611,000 USD X Estimate

Clarification of Response (if Necessary):

Executives' payroll and benefits and board member remuneration

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Arcadia Biosciences, Inc.	Steven F. Brandwein	Steve Brandwein	VP Finance & Administration	2009-08-03

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.